Spotlight: First study to compare two ketamine therapies for patients with severe depression
IV ketamine found to offer faster response with greater improvements than FDA-approved intranasal esketamine (Spravato)
More like this
Spotlight: "A Blueprint for Implementing Ketamine-Assisted Psychotherapy in Palliative Care: Design, Process, and Treatment Patterns of a Real-World Clinical Program" (Horowitz, et al, 2026)
"To our knowledge, this is the largest published cohort of KAP in an academic palliative care context. Our Pal-KAP experience suggests that KAP can be delivered safely and ethically, providing a practical blueprint for programs exploring innovative ways to address Psychospiritual distress (PSD)"
Rapid Improvement in Consciousness After Low-Dose Ketamine in a Patient With Acute Confusion: A Case Report (Khalafallah Khalid, et al, 2025)
"While anecdotal, such findings align with emerging literature and warrant further exploration of ketamine's neurocognitive effects beyond its established indications."
Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation (Irrmischer, et al, 2025)
"Findings indicate that individual psilocybin-assisted therapy has the potential for beneficial effects on mood and personality characteristics. Moreover, the study highlights the importance of subjective experiences and demographic factors in moderating this effect."
Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis (Elmosalamy, et al, 2025)
"Based on the currently available comparative evidence, which is almost entirely observational, IV ketamine and IN esketamine show comparable acute response and remission rates, though IV ketamine may act faster."
Unfolding States of Mind: A Dissociative-Psychedelic Model of Ketamine-Assisted Psychotherapy in Palliative Care (Gonçalves Campolina & Tuena de Oliveira, 2025)
Dissociative-psychedelic model offers a compassionate, pragmatic, theoretically grounded approach to relieving psychological & existential suffering in palliative care
Racemic Ketamine vs Esketamine in Treatment-Resistant Depression: The Overlooked Role of Arketamine (Tan, et al, 2025)
Evidence suggests that "IV racemic ketamine is more effective than IN esketamine in TRD; convergent preclinical and clinical findings support the hypothesis that arketamine plays a key role in this superiority and that ketamine’s antidepressant mechanisms extend beyond simple NMDAR antagonism."